FLT3 and acute myeloid leukemia: In a randomized phase 3 trial (QuANTUM-First), patients with newly diagnosed FLT3-ITD AML received Quizartinib as part of their treatment, which included standard anthracycline and cytarabine-based induction and consolidation, with quizartinib taken at a dose of 40 mg daily on specific days.